{
    "info": {
        "nct_id": "NCT04508647",
        "official_title": "Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response",
        "inclusion_criteria": "Disease Related\n\n1. Subjects with histologically documented Follicular lymphoma CD20+ (Grade 1, 2 or 3a) OR Marginal zone lymphoma CD20+ (nodal, extranodal or splenic) according to World Health Organization (WHO) criteria.\n2. Ann Arbor Stage II (Non-contiguous), III or IV disease\n3. Patients must have a whole body or limited whole body PET/CT scan performed within 42 days prior to registration. CT portion of PET/CT will be done with contrast based on current NCCN guidelines unless patient has borderline renal function or allergic to contrast dye.\n4. Patients must have bone marrow biopsy performed within 6 months prior to registration\n5. Measurable node must have an LDi greater than 1.5 cms. In the absence of nodal lesions, measurable extranodal disease should have an LDi greated than 1 cm. In patients with Splenic Marginal Zone lymphoma, in the absence of nodal lesions, spleen size should should be over 14 cms with evidence of lymphoma in the bone marrow biopsy.\n6. For low tumor burden lymphomas (as determined by GELF criteria) : Include patients diagnosed within 2 years of diagnosis. Low tumor burden patients diagnosed more than 2 years from study entry will be allowed provided patients have documented progression.\n\nPrior Therapy Criteria\n\n1. Patients must be untreated advanced stage disease (Stage III or Stage IV) or Stage II (noncontiguous). (Exception: Involved field or involved site radiation given for localized diagnosis is not considered a line of therapy).\n\nClinical/Laboratory Criteria\n\n1. Patients must be ≥ 18 years of age and be able to swallow and retain oral medication\n2. ECOG performance status of 0-2\n3. Patients must have adequate bone marrow function as evidenced by ANC ≥ 1000/µL and platelets ≥ 50,000µL and Hb >= 8g/dl within 28 days prior to registration unsupported by growth factors.\n4. Serum creatinine < 2.0 mg/dL or calculated creatinine clearance (CrCl) > 45 mL/min\n5. Patients must have adequate hepatic function obtained within 28 days prior to registration and documented by all of the following:\n\n   * Total bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma, Gilbert's syndrome, or medication related)\n   * Direct bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma)\n   * AST and ALT ≤ 2.5 x IULN (≤ 5 x IULN secondary to lymphoma)\n6. Patients must be willing to receive Pneumocystis jirovecii prophylaxis with sulfamethoxazole/trimethoprim, dapsone, and atovaquone or inhaled pentamadine, if they initiate combination umbralisib plus ublituximab (not for single agent ublituximab)\n7. Patients must have a complete history and physical examination within 28 days prior to registration\n8. Patients with follicular lymphoma must have the following components of Follicular Lymphoma International Prognostic Index (FLIPI) available from diagnosis, and collected again at time of registration:\n\n   * Age\n   * LDH\n   * Number of nodal groups involved\n   * Serum or plasma hemoglobin\n   * Ann Arbor Stage Additionally, patients must have beta2-microglobulin collected at time of registration and response assessment.\n9. Female subjects of reproductive potential must have a negative serum pregnancy test within 3 days prior to treatment start date. Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy at least six weeks ago) are exempt from pregnancy testing. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.\n10. Male and female subjects of reproductive potential who agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condoms, cervical ring, sponge, etc.) during the period of therapy.\n\nThe following are UNACCEPTABLE forms of contraception for females of childbearing potential:\n\n* natural family planning (rhythm method)\n* breastfeeding\n* fertility awareness\n* withdrawal For subjects, these birth control requirements must be adhered to for 4 months after the last dose of umbralisib and 12 months after the last dose of ublituximab, whichever is later.\n\nRegulatory Criteria\n\n1. Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "Disease-Related\n\n1. Transformed lymphoma; if clinical evidence of transformed lymphoma is present, transformation should be ruled out by biopsy of the suspicious lymph node/lesion\n2. Prior treatment for follicular lymphoma or marginal zone lymphoma (Except: involved field or site radiation therapy is allowed)\n3. Medically apparent central nervous system lymphoma or leptomeningeal disease\n4. Tumor burden where administration of other FDA approved anti-CD20 antibodies like singleagent rituximab would be inappropriate.\n5. Patients in need of immediate cytoreduction with chemotherapy based regimen.\n\nConcurrent Conditions\n\n1. Evidence of chronic active Hepatitis B (HBV, not including patients with prior hepatitis B vaccination; or positive serum Hepatitis B antibody) or chronic active Hepatitis C infection (HCV), active cytomegalovirus (CMV), or known history of HIV (or positive HIV test during screening). If HBc antibody is positive, the subject must be evaluated for the presence of HBV DNA by PCR. If HCV antibody is positive, the subject must be evaluated for the presence of HCV RNA by PCR. See Appendix: HEPATITIS B SEROLOGIC TEST RESULTS. If the subject is CMV IgG or CMV IgM positive, the subject must be evaluated for the presence of CMV DNA by PCR. Subjects with positive HBc antibody and negative HBV DNA by PCR are eligible. Subjects with positive HCV antibody and negative HCV RNA by PCR are eligible (subjects who are CMV IgG or CMV IgM positive but who are CMV DNA negative by PCR are eligible).\n2. Ongoing drug-induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by stones, or cirrhosis of the liver\n3. Inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)\n4. Irritable bowel syndrome with greater than 3 loose stools per day as a baseline\n5. Active autoimmune disease requiring ongoing immunosuppressive therapy including systemic corticosteroids (prednisone or equivalent ≤10 mg daily allowed as clinically warranted) within 12 months prior to enrollment. Patients are allowed to use topical or inhaled corticosteroids or levothyroxine for hypothyroidism or hypogylcemic agents for diabetes mellitis.\n6. Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study such as:\n\n   * Symptomatic, or history of documented congestive heart failure NYHA (New York Heart Association) functional classification III-IV [see Appendix: New York Heart Association Classifications]\n   * Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, CHF, or myocardial infarction within 6 months of enrollment.\n   * Concomitant use of medication known to cause QT prolongation or torsades de pointes should be used with caution and at investigator discretion.\n   * Poorly controlled or clinically significant atherosclerotic vascular disease including cerebrovascular accident (CVA), transient ischemic attack (TIA), angioplasty, cardiac or vascular stenting within 6 months of enrollment.\n7. Women who are pregnant or lactating\n8. History of other malignancies (including myelodysplastic syndromes) except:\n\n   * malignancy treated with curative intent and with no known active disease present for >2 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\n   * adequately treated non-melanoma skin cancer without evidence of disease\n   * adequately treated carcinoma in situ without evidence of disease\n   * localized prostate cancer and PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Age",
                "criterions": [
                    {
                        "exact_snippets": "Age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. ECOG performance status of 0-2",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance status of 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance status of 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* natural family planning (rhythm method)",
                "criterions": [
                    {
                        "exact_snippets": "natural family planning (rhythm method)",
                        "criterion": "contraceptive method",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "natural family planning (rhythm method)"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "natural family planning (rhythm method)",
                        "criterion": "contraceptive method",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "natural family planning (rhythm method)"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* fertility awareness",
                "criterions": [
                    {
                        "exact_snippets": "fertility awareness",
                        "criterion": "fertility awareness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "fertility awareness",
                        "criterion": "fertility awareness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Male and female subjects of reproductive potential who agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condoms, cervical ring, sponge, etc.) during the period of therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Male and female subjects of reproductive potential",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condoms, cervical ring, sponge, etc.) during the period of therapy",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "highly effective method of birth control",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condoms, cervical ring, sponge, etc.) during the period of therapy",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "barrier method of birth control",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condoms, cervical ring, sponge, etc.) during the period of therapy",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "during the period of therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Male and female subjects of reproductive potential",
                                "criterion": "reproductive potential",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condoms, cervical ring, sponge, etc.) during the period of therapy",
                                "criterion": "contraception use",
                                "requirement": {
                                    "requirement_type": "highly effective method of birth control",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condoms, cervical ring, sponge, etc.) during the period of therapy",
                                "criterion": "contraception use",
                                "requirement": {
                                    "requirement_type": "barrier method of birth control",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condoms, cervical ring, sponge, etc.) during the period of therapy",
                                "criterion": "contraception use",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": "during the period of therapy"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Direct bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma)",
                "criterions": [
                    {
                        "exact_snippets": "Direct bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma)",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x IULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Direct bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma)",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity (if secondary to lymphoma)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x IULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "Direct bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma)",
                    "criterion": "direct bilirubin",
                    "requirement": {
                        "requirement_type": "quantity (if secondary to lymphoma)",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 5,
                                    "unit": "x IULN"
                                }
                            ]
                        }
                    }
                },
                "then_criteria": null,
                "else_criteria": {
                    "exact_snippets": "Direct bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma)",
                    "criterion": "direct bilirubin",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 1.5,
                                    "unit": "x IULN"
                                }
                            ]
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Patients must have bone marrow biopsy performed within 6 months prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "bone marrow biopsy performed within 6 months prior to registration",
                        "criterion": "bone marrow biopsy",
                        "requirement": {
                            "requirement_type": "performance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bone marrow biopsy performed within 6 months prior to registration",
                        "criterion": "bone marrow biopsy",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to registration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "bone marrow biopsy performed within 6 months prior to registration",
                        "criterion": "bone marrow biopsy",
                        "requirement": {
                            "requirement_type": "performance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bone marrow biopsy performed within 6 months prior to registration",
                        "criterion": "bone marrow biopsy",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to registration"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Regulatory Criteria",
                "criterions": [
                    {
                        "exact_snippets": "Regulatory Criteria",
                        "criterion": "regulatory criteria",
                        "requirement": {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Regulatory Criteria",
                        "criterion": "regulatory criteria",
                        "requirement": {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* breastfeeding",
                "criterions": [
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "The following are UNACCEPTABLE forms of contraception for females of childbearing potential:",
                "criterions": [
                    {
                        "exact_snippets": "UNACCEPTABLE forms of contraception for females of childbearing potential",
                        "criterion": "form of contraception",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "UNACCEPTABLE forms of contraception for females of childbearing potential",
                        "criterion": "form of contraception",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": "females of childbearing potential"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "UNACCEPTABLE forms of contraception for females of childbearing potential",
                        "criterion": "form of contraception",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "UNACCEPTABLE forms of contraception for females of childbearing potential",
                        "criterion": "form of contraception",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": "females of childbearing potential"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Patients must have adequate hepatic function obtained within 28 days prior to registration and documented by all of the following:",
                "criterions": [
                    {
                        "exact_snippets": "adequate hepatic function",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "adequate hepatic function",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Number of nodal groups involved",
                "criterions": [
                    {
                        "exact_snippets": "Number of nodal groups involved",
                        "criterion": "number of nodal groups involved",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "specified number (not given in this line)"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Number of nodal groups involved",
                        "criterion": "number of nodal groups involved",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "specified number (not given in this line)"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Patients with follicular lymphoma must have the following components of Follicular Lymphoma International Prognostic Index (FLIPI) available from diagnosis, and collected again at time of registration:",
                "criterions": [
                    {
                        "exact_snippets": "components of Follicular Lymphoma International Prognostic Index (FLIPI) available from diagnosis, and collected again at time of registration",
                        "criterion": "FLIPI components",
                        "requirement": {
                            "requirement_type": "availability at diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "components of Follicular Lymphoma International Prognostic Index (FLIPI) available from diagnosis, and collected again at time of registration",
                        "criterion": "FLIPI components",
                        "requirement": {
                            "requirement_type": "availability at registration",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "components of Follicular Lymphoma International Prognostic Index (FLIPI) available from diagnosis, and collected again at time of registration",
                        "criterion": "FLIPI components",
                        "requirement": {
                            "requirement_type": "availability at diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "components of Follicular Lymphoma International Prognostic Index (FLIPI) available from diagnosis, and collected again at time of registration",
                        "criterion": "FLIPI components",
                        "requirement": {
                            "requirement_type": "availability at registration",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Clinical/Laboratory Criteria",
                "criterions": [
                    {
                        "exact_snippets": "Clinical/Laboratory Criteria",
                        "criterion": "clinical and laboratory criteria",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "meets protocol-specified clinical and laboratory criteria"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Clinical/Laboratory Criteria",
                        "criterion": "clinical and laboratory criteria",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "meets protocol-specified clinical and laboratory criteria"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* AST and ALT ≤ 2.5 x IULN (≤ 5 x IULN secondary to lymphoma)",
                "criterions": [
                    {
                        "exact_snippets": "AST and ALT ≤ 2.5 x IULN (≤ 5 x IULN secondary to lymphoma)",
                        "criterion": "AST",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x IULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST and ALT ≤ 2.5 x IULN (≤ 5 x IULN secondary to lymphoma)",
                        "criterion": "ALT",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x IULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "(≤ 5 x IULN secondary to lymphoma)",
                        "criterion": "AST (if secondary to lymphoma)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x IULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "(≤ 5 x IULN secondary to lymphoma)",
                        "criterion": "ALT (if secondary to lymphoma)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x IULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "AST and ALT ≤ 2.5 x IULN (≤ 5 x IULN secondary to lymphoma)",
                                "criterion": "AST",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2.5,
                                                "unit": "x IULN"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "AST and ALT ≤ 2.5 x IULN (≤ 5 x IULN secondary to lymphoma)",
                                "criterion": "ALT",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2.5,
                                                "unit": "x IULN"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "(≤ 5 x IULN secondary to lymphoma)",
                                "criterion": "AST (if secondary to lymphoma)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "x IULN"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "(≤ 5 x IULN secondary to lymphoma)",
                                "criterion": "ALT (if secondary to lymphoma)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "x IULN"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* LDH",
                "criterions": [
                    {
                        "exact_snippets": "LDH",
                        "criterion": "LDH",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "LDH",
                        "criterion": "LDH",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Prior Therapy Criteria",
                "criterions": [
                    {
                        "exact_snippets": "Prior Therapy Criteria",
                        "criterion": "prior therapy",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "criteria related to prior therapy will be specified"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior Therapy Criteria",
                        "criterion": "prior therapy",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "criteria related to prior therapy will be specified"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* withdrawal For subjects, these birth control requirements must be adhered to for 4 months after the last dose of umbralisib and 12 months after the last dose of ublituximab, whichever is later.",
                "criterions": [
                    {
                        "exact_snippets": "these birth control requirements must be adhered to for 4 months after the last dose of umbralisib and 12 months after the last dose of ublituximab, whichever is later.",
                        "criterion": "birth control requirements adherence",
                        "requirement": {
                            "requirement_type": "duration after last dose of umbralisib",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "these birth control requirements must be adhered to for 4 months after the last dose of umbralisib and 12 months after the last dose of ublituximab, whichever is later.",
                        "criterion": "birth control requirements adherence",
                        "requirement": {
                            "requirement_type": "duration after last dose of ublituximab",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "these birth control requirements must be adhered to for 4 months after the last dose of umbralisib and 12 months after the last dose of ublituximab, whichever is later.",
                        "criterion": "birth control requirements adherence",
                        "requirement": {
                            "requirement_type": "duration after last dose (whichever is later)",
                            "expected_value": "whichever is later"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "these birth control requirements must be adhered to for 4 months after the last dose of umbralisib and 12 months after the last dose of ublituximab, whichever is later.",
                                "criterion": "birth control requirements adherence",
                                "requirement": {
                                    "requirement_type": "duration after last dose of umbralisib",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "these birth control requirements must be adhered to for 4 months after the last dose of umbralisib and 12 months after the last dose of ublituximab, whichever is later.",
                                "criterion": "birth control requirements adherence",
                                "requirement": {
                                    "requirement_type": "duration after last dose of ublituximab",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "these birth control requirements must be adhered to for 4 months after the last dose of umbralisib and 12 months after the last dose of ublituximab, whichever is later.",
                        "criterion": "birth control requirements adherence",
                        "requirement": {
                            "requirement_type": "duration after last dose (whichever is later)",
                            "expected_value": "whichever is later"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Ann Arbor Stage Additionally, patients must have beta2-microglobulin collected at time of registration and response assessment.",
                "criterions": [
                    {
                        "exact_snippets": "Ann Arbor Stage",
                        "criterion": "Ann Arbor stage",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients must have beta2-microglobulin collected at time of registration and response assessment",
                        "criterion": "beta2-microglobulin collection",
                        "requirement": {
                            "requirement_type": "collection at registration",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients must have beta2-microglobulin collected at time of registration and response assessment",
                        "criterion": "beta2-microglobulin collection",
                        "requirement": {
                            "requirement_type": "collection at response assessment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ann Arbor Stage",
                        "criterion": "Ann Arbor stage",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "patients must have beta2-microglobulin collected at time of registration and response assessment",
                                "criterion": "beta2-microglobulin collection",
                                "requirement": {
                                    "requirement_type": "collection at registration",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "patients must have beta2-microglobulin collected at time of registration and response assessment",
                                "criterion": "beta2-microglobulin collection",
                                "requirement": {
                                    "requirement_type": "collection at response assessment",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Patients must have a complete history and physical examination within 28 days prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "complete history and physical examination within 28 days prior to registration",
                        "criterion": "history and physical examination",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "complete history and physical examination within 28 days prior to registration",
                        "criterion": "history and physical examination",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "complete history and physical examination within 28 days prior to registration",
                        "criterion": "history and physical examination",
                        "requirement": {
                            "requirement_type": "completeness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "complete history and physical examination within 28 days prior to registration",
                        "criterion": "history and physical examination",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Measurable node must have an LDi greater than 1.5 cms. In the absence of nodal lesions, measurable extranodal disease should have an LDi greated than 1 cm. In patients with Splenic Marginal Zone lymphoma, in the absence of nodal lesions, spleen size should should be over 14 cms with evidence of lymphoma in the bone marrow biopsy.",
                "criterions": [
                    {
                        "exact_snippets": "Measurable node must have an LDi greater than 1.5 cms.",
                        "criterion": "measurable node LDi",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "In the absence of nodal lesions, measurable extranodal disease should have an LDi greated than 1 cm.",
                        "criterion": "measurable extranodal disease LDi",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "In patients with Splenic Marginal Zone lymphoma, in the absence of nodal lesions, spleen size should should be over 14 cms",
                        "criterion": "spleen size (Splenic Marginal Zone lymphoma, in the absence of nodal lesions)",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "evidence of lymphoma in the bone marrow biopsy",
                        "criterion": "lymphoma in bone marrow biopsy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Measurable node must have an LDi greater than 1.5 cms.",
                                "criterion": "measurable node LDi",
                                "requirement": {
                                    "requirement_type": "size",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1.5,
                                        "unit": "cm"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "In the absence of nodal lesions, measurable extranodal disease should have an LDi greated than 1 cm.",
                                "criterion": "measurable extranodal disease LDi",
                                "requirement": {
                                    "requirement_type": "size",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "cm"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "In patients with Splenic Marginal Zone lymphoma, in the absence of nodal lesions, spleen size should should be over 14 cms",
                                "criterion": "spleen size (Splenic Marginal Zone lymphoma, in the absence of nodal lesions)",
                                "requirement": {
                                    "requirement_type": "size",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 14,
                                        "unit": "cm"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "evidence of lymphoma in the bone marrow biopsy",
                                "criterion": "lymphoma in bone marrow biopsy",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Serum creatinine < 2.0 mg/dL or calculated creatinine clearance (CrCl) > 45 mL/min",
                "criterions": [
                    {
                        "exact_snippets": "Serum creatinine < 2.0 mg/dL",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "mg/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "calculated creatinine clearance (CrCl) > 45 mL/min",
                        "criterion": "calculated creatinine clearance (CrCl)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serum creatinine < 2.0 mg/dL",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "mg/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "calculated creatinine clearance (CrCl) > 45 mL/min",
                        "criterion": "calculated creatinine clearance (CrCl)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Disease Related",
                "criterions": [
                    {
                        "exact_snippets": "Disease Related",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "relatedness",
                            "expected_value": "related"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Disease Related",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "relatedness",
                            "expected_value": "related"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. For low tumor burden lymphomas (as determined by GELF criteria) : Include patients diagnosed within 2 years of diagnosis. Low tumor burden patients diagnosed more than 2 years from study entry will be allowed provided patients have documented progression.",
                "criterions": [
                    {
                        "exact_snippets": "low tumor burden lymphomas (as determined by GELF criteria)",
                        "criterion": "tumor burden (lymphoma)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "low"
                        }
                    },
                    {
                        "exact_snippets": "low tumor burden lymphomas (as determined by GELF criteria)",
                        "criterion": "tumor burden (lymphoma)",
                        "requirement": {
                            "requirement_type": "assessment_method",
                            "expected_value": "GELF criteria"
                        }
                    },
                    {
                        "exact_snippets": "diagnosed within 2 years of diagnosis",
                        "criterion": "time since lymphoma diagnosis",
                        "requirement": {
                            "requirement_type": "time_since_diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Low tumor burden patients diagnosed more than 2 years from study entry will be allowed provided patients have documented progression",
                        "criterion": "disease progression (in low tumor burden patients diagnosed >2 years ago)",
                        "requirement": {
                            "requirement_type": "time_since_diagnosis",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Low tumor burden patients diagnosed more than 2 years from study entry will be allowed provided patients have documented progression",
                        "criterion": "disease progression (in low tumor burden patients diagnosed >2 years ago)",
                        "requirement": {
                            "requirement_type": "progression_documented",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "low tumor burden lymphomas (as determined by GELF criteria)",
                                "criterion": "tumor burden (lymphoma)",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "low"
                                }
                            },
                            {
                                "exact_snippets": "low tumor burden lymphomas (as determined by GELF criteria)",
                                "criterion": "tumor burden (lymphoma)",
                                "requirement": {
                                    "requirement_type": "assessment_method",
                                    "expected_value": "GELF criteria"
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "diagnosed within 2 years of diagnosis",
                                "criterion": "time since lymphoma diagnosis",
                                "requirement": {
                                    "requirement_type": "time_since_diagnosis",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "years"
                                    }
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Low tumor burden patients diagnosed more than 2 years from study entry will be allowed provided patients have documented progression",
                                        "criterion": "disease progression (in low tumor burden patients diagnosed >2 years ago)",
                                        "requirement": {
                                            "requirement_type": "time_since_diagnosis",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 2,
                                                "unit": "years"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Low tumor burden patients diagnosed more than 2 years from study entry will be allowed provided patients have documented progression",
                                        "criterion": "disease progression (in low tumor burden patients diagnosed >2 years ago)",
                                        "requirement": {
                                            "requirement_type": "progression_documented",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "7. Women who are pregnant or lactating",
                "criterions": [
                    {
                        "exact_snippets": "Women who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Women who are ... lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Women who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Women who are ... lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)",
                "criterions": [
                    {
                        "exact_snippets": "Inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)",
                        "criterion": "inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Crohn's disease",
                        "criterion": "Crohn's disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative colitis",
                        "criterion": "ulcerative colitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)",
                        "criterion": "inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Crohn's disease",
                        "criterion": "Crohn's disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ulcerative colitis",
                        "criterion": "ulcerative colitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* malignancy treated with curative intent and with no known active disease present for >2 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician",
                "criterions": [
                    {
                        "exact_snippets": "malignancy treated with curative intent",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        }
                    },
                    {
                        "exact_snippets": "no known active disease present for >2 years before the first dose of study drug",
                        "criterion": "active disease",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no known active disease present for >2 years before the first dose of study drug",
                        "criterion": "active disease",
                        "requirement": {
                            "requirement_type": "duration_of_absence",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "felt to be at low risk for recurrence by treating physician",
                        "criterion": "risk of recurrence",
                        "requirement": {
                            "requirement_type": "risk_level",
                            "expected_value": "low"
                        }
                    },
                    {
                        "exact_snippets": "felt to be at low risk for recurrence by treating physician",
                        "criterion": "risk of recurrence",
                        "requirement": {
                            "requirement_type": "physician_assessment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "malignancy treated with curative intent",
                                "criterion": "malignancy",
                                "requirement": {
                                    "requirement_type": "treatment_intent",
                                    "expected_value": "curative"
                                }
                            },
                            {
                                "exact_snippets": "no known active disease present for >2 years before the first dose of study drug",
                                "criterion": "active disease",
                                "requirement": {
                                    "requirement_type": "absence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "no known active disease present for >2 years before the first dose of study drug",
                                "criterion": "active disease",
                                "requirement": {
                                    "requirement_type": "duration_of_absence",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 2,
                                        "unit": "years"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "felt to be at low risk for recurrence by treating physician",
                                "criterion": "risk of recurrence",
                                "requirement": {
                                    "requirement_type": "risk_level",
                                    "expected_value": "low"
                                }
                            },
                            {
                                "exact_snippets": "felt to be at low risk for recurrence by treating physician",
                                "criterion": "risk of recurrence",
                                "requirement": {
                                    "requirement_type": "physician_assessment",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* adequately treated carcinoma in situ without evidence of disease",
                "criterions": [
                    {
                        "exact_snippets": "adequately treated carcinoma in situ",
                        "criterion": "carcinoma in situ",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    },
                    {
                        "exact_snippets": "without evidence of disease",
                        "criterion": "evidence of disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "adequately treated carcinoma in situ",
                        "criterion": "carcinoma in situ",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    },
                    {
                        "exact_snippets": "without evidence of disease",
                        "criterion": "evidence of disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Medically apparent central nervous system lymphoma or leptomeningeal disease",
                "criterions": [
                    {
                        "exact_snippets": "Medically apparent central nervous system lymphoma",
                        "criterion": "central nervous system lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Medically apparent central nervous system lymphoma",
                        "criterion": "central nervous system lymphoma",
                        "requirement": {
                            "requirement_type": "medical_apparency",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "leptomeningeal disease",
                        "criterion": "leptomeningeal disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Medically apparent central nervous system lymphoma",
                                "criterion": "central nervous system lymphoma",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Medically apparent central nervous system lymphoma",
                                "criterion": "central nervous system lymphoma",
                                "requirement": {
                                    "requirement_type": "medical_apparency",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "leptomeningeal disease",
                        "criterion": "leptomeningeal disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Tumor burden where administration of other FDA approved anti-CD20 antibodies like singleagent rituximab would be inappropriate.",
                "criterions": [
                    {
                        "exact_snippets": "Tumor burden where administration of other FDA approved anti-CD20 antibodies like singleagent rituximab would be inappropriate.",
                        "criterion": "tumor burden",
                        "requirement": {
                            "requirement_type": "appropriateness of anti-CD20 antibody therapy",
                            "expected_value": "inappropriate"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Tumor burden where administration of other FDA approved anti-CD20 antibodies like singleagent rituximab would be inappropriate.",
                        "criterion": "tumor burden",
                        "requirement": {
                            "requirement_type": "appropriateness of anti-CD20 antibody therapy",
                            "expected_value": "inappropriate"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Disease-Related",
                "criterions": [
                    {
                        "exact_snippets": "Disease-Related",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "relatedness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Disease-Related",
                    "criterion": "disease",
                    "requirement": {
                        "requirement_type": "relatedness",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "8. History of other malignancies (including myelodysplastic syndromes) except:",
                "criterions": [
                    {
                        "exact_snippets": "History of other malignancies (including myelodysplastic syndromes)",
                        "criterion": "history of other malignancies",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myelodysplastic syndromes",
                        "criterion": "history of myelodysplastic syndromes",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of other malignancies (including myelodysplastic syndromes)",
                        "criterion": "history of other malignancies",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myelodysplastic syndromes",
                        "criterion": "history of myelodysplastic syndromes",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Symptomatic, or history of documented congestive heart failure NYHA (New York Heart Association) functional classification III-IV [see Appendix: New York Heart Association Classifications]",
                "criterions": [
                    {
                        "exact_snippets": "Symptomatic, or history of documented congestive heart failure NYHA (New York Heart Association) functional classification III-IV",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "history of diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Symptomatic, or history of documented congestive heart failure NYHA (New York Heart Association) functional classification III-IV",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "NYHA functional classification",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "NYHA class"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Symptomatic, or history of documented congestive heart failure NYHA (New York Heart Association) functional classification III-IV",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "history of diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Symptomatic, or history of documented congestive heart failure NYHA (New York Heart Association) functional classification III-IV",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "NYHA functional classification",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "NYHA class"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, CHF, or myocardial infarction within 6 months of enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Significant cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled or symptomatic arrhythmias",
                        "criterion": "arrhythmias",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled or symptomatic arrhythmias",
                        "criterion": "arrhythmias",
                        "requirement": {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "CHF",
                        "criterion": "congestive heart failure (CHF)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction within 6 months of enrollment",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Significant cardiovascular disease",
                                "criterion": "cardiovascular disease",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "significant"
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "uncontrolled or symptomatic arrhythmias",
                                                "criterion": "arrhythmias",
                                                "requirement": {
                                                    "requirement_type": "control",
                                                    "expected_value": false
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "uncontrolled or symptomatic arrhythmias",
                                                "criterion": "arrhythmias",
                                                "requirement": {
                                                    "requirement_type": "symptoms",
                                                    "expected_value": true
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "exact_snippets": "CHF",
                                        "criterion": "congestive heart failure (CHF)",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "myocardial infarction within 6 months of enrollment",
                                        "criterion": "myocardial infarction",
                                        "requirement": {
                                            "requirement_type": "recency",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 6,
                                                "unit": "months"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Concurrent Conditions",
                "criterions": [
                    {
                        "exact_snippets": "Concurrent Conditions",
                        "criterion": "concurrent conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Concurrent Conditions",
                        "criterion": "concurrent conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* adequately treated non-melanoma skin cancer without evidence of disease",
                "criterions": [
                    {
                        "exact_snippets": "adequately treated non-melanoma skin cancer",
                        "criterion": "non-melanoma skin cancer",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    },
                    {
                        "exact_snippets": "without evidence of disease",
                        "criterion": "evidence of disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "adequately treated non-melanoma skin cancer",
                            "criterion": "non-melanoma skin cancer",
                            "requirement": {
                                "requirement_type": "treatment status",
                                "expected_value": "adequately treated"
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "without evidence of disease",
                            "criterion": "evidence of disease",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Ongoing drug-induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by stones, or cirrhosis of the liver",
                "criterions": [
                    {
                        "exact_snippets": "Ongoing drug-induced liver injury",
                        "criterion": "drug-induced liver injury",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Ongoing drug-induced liver injury",
                        "criterion": "drug-induced liver injury",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    },
                    {
                        "exact_snippets": "alcoholic liver disease",
                        "criterion": "alcoholic liver disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "non-alcoholic steatohepatitis",
                        "criterion": "non-alcoholic steatohepatitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "primary biliary cirrhosis",
                        "criterion": "primary biliary cirrhosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "extrahepatic obstruction caused by stones",
                        "criterion": "extrahepatic obstruction caused by stones",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cirrhosis of the liver",
                        "criterion": "cirrhosis of the liver",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Ongoing drug-induced liver injury",
                                "criterion": "drug-induced liver injury",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Ongoing drug-induced liver injury",
                                "criterion": "drug-induced liver injury",
                                "requirement": {
                                    "requirement_type": "status",
                                    "expected_value": "ongoing"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "alcoholic liver disease",
                        "criterion": "alcoholic liver disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "non-alcoholic steatohepatitis",
                        "criterion": "non-alcoholic steatohepatitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "primary biliary cirrhosis",
                        "criterion": "primary biliary cirrhosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "extrahepatic obstruction caused by stones",
                        "criterion": "extrahepatic obstruction caused by stones",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cirrhosis of the liver",
                        "criterion": "cirrhosis of the liver",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Prior treatment for follicular lymphoma or marginal zone lymphoma (Except: involved field or site radiation therapy is allowed)",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment for follicular lymphoma or marginal zone lymphoma (Except: involved field or site radiation therapy is allowed)",
                        "criterion": "prior treatment for follicular lymphoma or marginal zone lymphoma",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment for follicular lymphoma or marginal zone lymphoma (Except: involved field or site radiation therapy is allowed)",
                        "criterion": "prior treatment for follicular lymphoma or marginal zone lymphoma",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "involved field or site radiation therapy is allowed"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Prior treatment for follicular lymphoma or marginal zone lymphoma (Except: involved field or site radiation therapy is allowed)",
                                "criterion": "prior treatment for follicular lymphoma or marginal zone lymphoma",
                                "requirement": {
                                    "requirement_type": "absence",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "Prior treatment for follicular lymphoma or marginal zone lymphoma (Except: involved field or site radiation therapy is allowed)",
                                    "criterion": "prior treatment for follicular lymphoma or marginal zone lymphoma",
                                    "requirement": {
                                        "requirement_type": "exception",
                                        "expected_value": "involved field or site radiation therapy is allowed"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* localized prostate cancer and PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry",
                "criterions": [
                    {
                        "exact_snippets": "localized prostate cancer",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "localization",
                            "expected_value": "localized"
                        }
                    },
                    {
                        "exact_snippets": "PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.0,
                                "unit": "mg/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "consecutive measurements",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "measurement interval",
                            "expected_value": "at least 3 months apart"
                        }
                    },
                    {
                        "exact_snippets": "PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "recency of most recent measurement",
                            "expected_value": "within 4 weeks of study entry"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "localized prostate cancer",
                                "criterion": "prostate cancer",
                                "requirement": {
                                    "requirement_type": "localization",
                                    "expected_value": "localized"
                                }
                            },
                            {
                                "exact_snippets": "PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry",
                                "criterion": "PSA level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 1.0,
                                        "unit": "mg/dL"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry",
                                "criterion": "PSA level",
                                "requirement": {
                                    "requirement_type": "consecutive measurements",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry",
                                "criterion": "PSA level",
                                "requirement": {
                                    "requirement_type": "measurement interval",
                                    "expected_value": "at least 3 months apart"
                                }
                            },
                            {
                                "exact_snippets": "PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry",
                                "criterion": "PSA level",
                                "requirement": {
                                    "requirement_type": "recency of most recent measurement",
                                    "expected_value": "within 4 weeks of study entry"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study such as:",
                "criterions": [
                    {
                        "exact_snippets": "Any severe and/or uncontrolled medical conditions",
                        "criterion": "medical conditions",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "Any severe and/or uncontrolled medical conditions",
                        "criterion": "medical conditions",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "other conditions that could affect participation in the study",
                        "criterion": "other conditions affecting participation",
                        "requirement": {
                            "requirement_type": "impact_on_participation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any severe and/or uncontrolled medical conditions",
                                "criterion": "medical conditions",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "severe"
                                }
                            },
                            {
                                "exact_snippets": "Any severe and/or uncontrolled medical conditions",
                                "criterion": "medical conditions",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "other conditions that could affect participation in the study",
                        "criterion": "other conditions affecting participation",
                        "requirement": {
                            "requirement_type": "impact_on_participation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Poorly controlled or clinically significant atherosclerotic vascular disease including cerebrovascular accident (CVA), transient ischemic attack (TIA), angioplasty, cardiac or vascular stenting within 6 months of enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Poorly controlled or clinically significant atherosclerotic vascular disease",
                        "criterion": "atherosclerotic vascular disease",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    },
                    {
                        "exact_snippets": "Poorly controlled or clinically significant atherosclerotic vascular disease",
                        "criterion": "atherosclerotic vascular disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cerebrovascular accident (CVA)",
                        "criterion": "cerebrovascular accident (CVA)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "transient ischemic attack (TIA)",
                        "criterion": "transient ischemic attack (TIA)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "angioplasty within 6 months of enrollment",
                        "criterion": "angioplasty",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "cardiac or vascular stenting within 6 months of enrollment",
                        "criterion": "cardiac stenting",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "cardiac or vascular stenting within 6 months of enrollment",
                        "criterion": "vascular stenting",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Poorly controlled or clinically significant atherosclerotic vascular disease",
                                "criterion": "atherosclerotic vascular disease",
                                "requirement": {
                                    "requirement_type": "control",
                                    "expected_value": "poorly controlled"
                                }
                            },
                            {
                                "exact_snippets": "Poorly controlled or clinically significant atherosclerotic vascular disease",
                                "criterion": "atherosclerotic vascular disease",
                                "requirement": {
                                    "requirement_type": "clinical significance",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "cerebrovascular accident (CVA)",
                        "criterion": "cerebrovascular accident (CVA)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "transient ischemic attack (TIA)",
                        "criterion": "transient ischemic attack (TIA)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "angioplasty within 6 months of enrollment",
                        "criterion": "angioplasty",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "cardiac or vascular stenting within 6 months of enrollment",
                        "criterion": "cardiac stenting",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "cardiac or vascular stenting within 6 months of enrollment",
                        "criterion": "vascular stenting",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Irritable bowel syndrome with greater than 3 loose stools per day as a baseline",
                "criterions": [
                    {
                        "exact_snippets": "Irritable bowel syndrome",
                        "criterion": "irritable bowel syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "greater than 3 loose stools per day as a baseline",
                        "criterion": "loose stools per day (baseline)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "loose stools/day"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Irritable bowel syndrome",
                                "criterion": "irritable bowel syndrome",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "greater than 3 loose stools per day as a baseline",
                                "criterion": "loose stools per day (baseline)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 3,
                                        "unit": "loose stools/day"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Patients in need of immediate cytoreduction with chemotherapy based regimen.",
                "criterions": [
                    {
                        "exact_snippets": "Patients in need of immediate cytoreduction with chemotherapy based regimen",
                        "criterion": "need for immediate cytoreduction with chemotherapy based regimen",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Patients in need of immediate cytoreduction with chemotherapy based regimen",
                    "criterion": "need for immediate cytoreduction with chemotherapy based regimen",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Concomitant use of medication known to cause QT prolongation or torsades de pointes should be used with caution and at investigator discretion.",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant use of medication known to cause QT prolongation or torsades de pointes",
                        "criterion": "concomitant use of medication known to cause QT prolongation or torsades de pointes",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": "should be used with caution and at investigator discretion"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Concomitant use of medication known to cause QT prolongation or torsades de pointes",
                    "criterion": "concomitant use of medication known to cause QT prolongation or torsades de pointes",
                    "requirement": {
                        "requirement_type": "use",
                        "expected_value": "should be used with caution and at investigator discretion"
                    }
                }
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "1. Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.",
                "criterions": [
                    {
                        "exact_snippets": "Patients must be informed of the investigational nature of this study",
                        "criterion": "patient informed of investigational nature",
                        "requirement": {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must sign and give written informed consent in accordance with institutional and federal guidelines",
                        "criterion": "written informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must sign and give written informed consent in accordance with institutional and federal guidelines",
                        "criterion": "written informed consent",
                        "requirement": {
                            "requirement_type": "compliance with guidelines",
                            "expected_value": [
                                "institutional",
                                "federal"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. Ann Arbor Stage II (Non-contiguous), III or IV disease",
                "criterions": [
                    {
                        "exact_snippets": "Ann Arbor Stage II (Non-contiguous), III or IV disease",
                        "criterion": "Ann Arbor stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "II (Non-contiguous)",
                                "III",
                                "IV"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Serum or plasma hemoglobin",
                "criterions": [
                    {
                        "exact_snippets": "Serum or plasma hemoglobin",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Serum or plasma hemoglobin",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "sample_type",
                            "expected_value": [
                                "serum",
                                "plasma"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Patients must have a whole body or limited whole body PET/CT scan performed within 42 days prior to registration. CT portion of PET/CT will be done with contrast based on current NCCN guidelines unless patient has borderline renal function or allergic to contrast dye.",
                "criterions": [
                    {
                        "exact_snippets": "Patients must have a whole body or limited whole body PET/CT scan performed within 42 days prior to registration.",
                        "criterion": "PET/CT scan",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "whole body",
                                "limited whole body"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Patients must have a whole body or limited whole body PET/CT scan performed within 42 days prior to registration.",
                        "criterion": "PET/CT scan",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 42,
                                "unit": "days prior to registration"
                            }
                        }
                    },
                    {
                        "exact_snippets": "CT portion of PET/CT will be done with contrast ... unless patient has borderline renal function or allergic to contrast dye.",
                        "criterion": "CT portion of PET/CT with contrast",
                        "requirement": {
                            "requirement_type": "use of contrast",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "CT portion of PET/CT will be done with contrast ... unless patient has borderline renal function or allergic to contrast dye.",
                        "criterion": "CT portion of PET/CT with contrast",
                        "requirement": {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "borderline renal function",
                                "allergic to contrast dye"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Total bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma, Gilbert's syndrome, or medication related)",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma, Gilbert's syndrome, or medication related)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x IULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma, Gilbert's syndrome, or medication related)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity (if secondary to lymphoma, Gilbert's syndrome, or medication related)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x IULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "or_criteria": [
                        {
                            "exact_snippets": "Total bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma, Gilbert's syndrome, or medication related)",
                            "criterion": "quantity (if secondary to lymphoma, Gilbert's syndrome, or medication related)",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": true
                            }
                        }
                    ]
                },
                "then_criteria": {
                    "exact_snippets": "Total bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma, Gilbert's syndrome, or medication related)",
                    "criterion": "total bilirubin",
                    "requirement": {
                        "requirement_type": "quantity (if secondary to lymphoma, Gilbert's syndrome, or medication related)",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 5,
                                    "unit": "x IULN"
                                }
                            ]
                        }
                    }
                },
                "else_criteria": {
                    "exact_snippets": "Total bilirubin ≤ 1.5 x IULN (≤ 5 x IULN if secondary to lymphoma, Gilbert's syndrome, or medication related)",
                    "criterion": "total bilirubin",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 1.5,
                                    "unit": "x IULN"
                                }
                            ]
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Patients must have adequate bone marrow function as evidenced by ANC ≥ 1000/µL and platelets ≥ 50,000µL and Hb >= 8g/dl within 28 days prior to registration unsupported by growth factors.",
                "criterions": [
                    {
                        "exact_snippets": "adequate bone marrow function as evidenced by ANC ≥ 1000/µL",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "/µL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "platelets ≥ 50,000µL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50000,
                                "unit": "/µL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hb >= 8g/dl within 28 days prior to registration unsupported by growth factors",
                        "criterion": "hemoglobin (Hb) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "g/dl"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hb >= 8g/dl within 28 days prior to registration unsupported by growth factors",
                        "criterion": "hemoglobin (Hb) level",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 28 days prior to registration"
                        }
                    },
                    {
                        "exact_snippets": "Hb >= 8g/dl within 28 days prior to registration unsupported by growth factors",
                        "criterion": "hemoglobin (Hb) level",
                        "requirement": {
                            "requirement_type": "support by growth factors",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "adequate bone marrow function as evidenced by ANC \u001e 1000/\u00181",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "/\u00181"
                            }
                        }
                    },
                    {
                        "exact_snippets": "platelets \u001e 50,000\u00181",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50000,
                                "unit": "/\u00181"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Hb >= 8g/dl within 28 days prior to registration unsupported by growth factors",
                                "criterion": "hemoglobin (Hb) level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": "g/dl"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Hb >= 8g/dl within 28 days prior to registration unsupported by growth factors",
                                "criterion": "hemoglobin (Hb) level",
                                "requirement": {
                                    "requirement_type": "time frame",
                                    "expected_value": "within 28 days prior to registration"
                                }
                            },
                            {
                                "exact_snippets": "Hb >= 8g/dl within 28 days prior to registration unsupported by growth factors",
                                "criterion": "hemoglobin (Hb) level",
                                "requirement": {
                                    "requirement_type": "support by growth factors",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Patients must be willing to receive Pneumocystis jirovecii prophylaxis with sulfamethoxazole/trimethoprim, dapsone, and atovaquone or inhaled pentamadine, if they initiate combination umbralisib plus ublituximab (not for single agent ublituximab)",
                "criterions": [
                    {
                        "exact_snippets": "Patients must be willing to receive Pneumocystis jirovecii prophylaxis with sulfamethoxazole/trimethoprim, dapsone, and atovaquone or inhaled pentamadine, if they initiate combination umbralisib plus ublituximab (not for single agent ublituximab)",
                        "criterion": "willingness to receive Pneumocystis jirovecii prophylaxis",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients must be willing to receive Pneumocystis jirovecii prophylaxis with sulfamethoxazole/trimethoprim, dapsone, and atovaquone or inhaled pentamadine, if they initiate combination umbralisib plus ublituximab (not for single agent ublituximab)",
                        "criterion": "willingness to receive Pneumocystis jirovecii prophylaxis",
                        "requirement": {
                            "requirement_type": "prophylaxis agents",
                            "expected_value": [
                                "sulfamethoxazole/trimethoprim",
                                "dapsone",
                                "atovaquone",
                                "inhaled pentamadine"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Patients must be willing to receive Pneumocystis jirovecii prophylaxis with sulfamethoxazole/trimethoprim, dapsone, and atovaquone or inhaled pentamadine, if they initiate combination umbralisib plus ublituximab (not for single agent ublituximab)",
                        "criterion": "willingness to receive Pneumocystis jirovecii prophylaxis",
                        "requirement": {
                            "requirement_type": "condition for requirement",
                            "expected_value": "if they initiate combination umbralisib plus ublituximab"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Patients must be ≥ 18 years of age and be able to swallow and retain oral medication",
                "criterions": [
                    {
                        "exact_snippets": "Patients must be ≥ 18 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "be able to swallow and retain oral medication",
                        "criterion": "ability to swallow and retain oral medication",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients must be \u001e 18 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "be able to swallow and retain oral medication",
                        "criterion": "ability to swallow and retain oral medication",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Female subjects of reproductive potential must have a negative serum pregnancy test within 3 days prior to treatment start date. Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy at least six weeks ago) are exempt from pregnancy testing. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.",
                "criterions": [
                    {
                        "exact_snippets": "Female subjects of reproductive potential must have a negative serum pregnancy test within 3 days prior to treatment start date.",
                        "criterion": "serum pregnancy test result",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Female subjects of reproductive potential must have a negative serum pregnancy test within 3 days prior to treatment start date.",
                        "criterion": "serum pregnancy test result",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "days prior to treatment start date"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy at least six weeks ago) are exempt from pregnancy testing.",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "non-reproductive"
                        }
                    },
                    {
                        "exact_snippets": "post-menopausal by history - no menses for ≥1 year",
                        "criterion": "menstrual history",
                        "requirement": {
                            "requirement_type": "absence of menses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of hysterectomy",
                        "criterion": "hysterectomy history",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of bilateral tubal ligation",
                        "criterion": "bilateral tubal ligation history",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of bilateral oophorectomy at least six weeks ago",
                        "criterion": "bilateral oophorectomy history",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of bilateral oophorectomy at least six weeks ago",
                        "criterion": "bilateral oophorectomy history",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.",
                        "criterion": "hormone level assessment after oophorectomy",
                        "requirement": {
                            "requirement_type": "confirmation of non-reproductive status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "not_criteria": {
                                    "not_criteria": {
                                        "exact_snippets": "Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for \u001e1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy at least six weeks ago) are exempt from pregnancy testing.",
                                        "criterion": "reproductive potential",
                                        "requirement": {
                                            "requirement_type": "status",
                                            "expected_value": "non-reproductive"
                                        }
                                    }
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Female subjects of reproductive potential must have a negative serum pregnancy test within 3 days prior to treatment start date.",
                                        "criterion": "serum pregnancy test result",
                                        "requirement": {
                                            "requirement_type": "result",
                                            "expected_value": "negative"
                                        }
                                    },
                                    {
                                        "exact_snippets": "Female subjects of reproductive potential must have a negative serum pregnancy test within 3 days prior to treatment start date.",
                                        "criterion": "serum pregnancy test result",
                                        "requirement": {
                                            "requirement_type": "timing",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 3,
                                                "unit": "days prior to treatment start date"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "post-menopausal by history - no menses for \u001e1 year",
                                "criterion": "menstrual history",
                                "requirement": {
                                    "requirement_type": "absence of menses",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "year"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "history of hysterectomy",
                                "criterion": "hysterectomy history",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "history of bilateral tubal ligation",
                                "criterion": "bilateral tubal ligation history",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "history of bilateral oophorectomy at least six weeks ago",
                                        "criterion": "bilateral oophorectomy history",
                                        "requirement": {
                                            "requirement_type": "history",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "history of bilateral oophorectomy at least six weeks ago",
                                        "criterion": "bilateral oophorectomy history",
                                        "requirement": {
                                            "requirement_type": "time since procedure",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 6,
                                                "unit": "weeks"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.",
                                        "criterion": "hormone level assessment after oophorectomy",
                                        "requirement": {
                                            "requirement_type": "confirmation of non-reproductive status",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Patients must be untreated advanced stage disease (Stage III or Stage IV) or Stage II (noncontiguous). (Exception: Involved field or involved site radiation given for localized diagnosis is not considered a line of therapy).",
                "criterions": [
                    {
                        "exact_snippets": "untreated advanced stage disease (Stage III or Stage IV)",
                        "criterion": "disease stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "Stage III",
                                "Stage IV"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "untreated advanced stage disease (Stage III or Stage IV)",
                        "criterion": "disease stage",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    },
                    {
                        "exact_snippets": "Stage II (noncontiguous)",
                        "criterion": "disease stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": "Stage II"
                        }
                    },
                    {
                        "exact_snippets": "Stage II (noncontiguous)",
                        "criterion": "disease stage",
                        "requirement": {
                            "requirement_type": "contiguity",
                            "expected_value": "noncontiguous"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Subjects with histologically documented Follicular lymphoma CD20+ (Grade 1, 2 or 3a) OR Marginal zone lymphoma CD20+ (nodal, extranodal or splenic) according to World Health Organization (WHO) criteria.",
                "criterions": [
                    {
                        "exact_snippets": "histologically documented Follicular lymphoma CD20+ (Grade 1, 2 or 3a)",
                        "criterion": "Follicular lymphoma",
                        "requirement": {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "histologically documented Follicular lymphoma CD20+ (Grade 1, 2 or 3a)",
                        "criterion": "Follicular lymphoma",
                        "requirement": {
                            "requirement_type": "CD20 expression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "histologically documented Follicular lymphoma CD20+ (Grade 1, 2 or 3a)",
                        "criterion": "Follicular lymphoma",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": [
                                "1",
                                "2",
                                "3a"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Marginal zone lymphoma CD20+ (nodal, extranodal or splenic)",
                        "criterion": "Marginal zone lymphoma",
                        "requirement": {
                            "requirement_type": "CD20 expression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Marginal zone lymphoma CD20+ (nodal, extranodal or splenic)",
                        "criterion": "Marginal zone lymphoma",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "nodal",
                                "extranodal",
                                "splenic"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "5. Active autoimmune disease requiring ongoing immunosuppressive therapy including systemic corticosteroids (prednisone or equivalent ≤10 mg daily allowed as clinically warranted) within 12 months prior to enrollment. Patients are allowed to use topical or inhaled corticosteroids or levothyroxine for hypothyroidism or hypogylcemic agents for diabetes mellitis.",
                "criterions": [
                    {
                        "exact_snippets": "Active autoimmune disease requiring ongoing immunosuppressive therapy including systemic corticosteroids (prednisone or equivalent ≤10 mg daily allowed as clinically warranted) within 12 months prior to enrollment.",
                        "criterion": "active autoimmune disease requiring ongoing immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "prednisone or equivalent ≤10 mg daily allowed as clinically warranted",
                        "criterion": "systemic corticosteroid dose",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg daily"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients are allowed to use topical or inhaled corticosteroids or levothyroxine for hypothyroidism or hypogylcemic agents for diabetes mellitis.",
                        "criterion": "use of topical or inhaled corticosteroids, levothyroxine, or hypoglycemic agents",
                        "requirement": {
                            "requirement_type": "allowed_medications",
                            "expected_value": [
                                "topical corticosteroids",
                                "inhaled corticosteroids",
                                "levothyroxine",
                                "hypoglycemic agents"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Transformed lymphoma; if clinical evidence of transformed lymphoma is present, transformation should be ruled out by biopsy of the suspicious lymph node/lesion",
                "criterions": [
                    {
                        "exact_snippets": "Transformed lymphoma",
                        "criterion": "transformed lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "if clinical evidence of transformed lymphoma is present, transformation should be ruled out by biopsy of the suspicious lymph node/lesion",
                        "criterion": "transformed lymphoma",
                        "requirement": {
                            "requirement_type": "diagnosis confirmation by biopsy",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Transformed lymphoma",
                        "criterion": "transformed lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "if clinical evidence of transformed lymphoma is present, transformation should be ruled out by biopsy of the suspicious lymph node/lesion",
                                "criterion": "transformed lymphoma",
                                "requirement": {
                                    "requirement_type": "diagnosis confirmation by biopsy",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "if clinical evidence of transformed lymphoma is present, transformation should be ruled out by biopsy of the suspicious lymph node/lesion",
                                "criterion": "transformed lymphoma",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Evidence of chronic active Hepatitis B (HBV, not including patients with prior hepatitis B vaccination; or positive serum Hepatitis B antibody) or chronic active Hepatitis C infection (HCV), active cytomegalovirus (CMV), or known history of HIV (or positive HIV test during screening). If HBc antibody is positive, the subject must be evaluated for the presence of HBV DNA by PCR. If HCV antibody is positive, the subject must be evaluated for the presence of HCV RNA by PCR. See Appendix: HEPATITIS B SEROLOGIC TEST RESULTS. If the subject is CMV IgG or CMV IgM positive, the subject must be evaluated for the presence of CMV DNA by PCR. Subjects with positive HBc antibody and negative HBV DNA by PCR are eligible. Subjects with positive HCV antibody and negative HCV RNA by PCR are eligible (subjects who are CMV IgG or CMV IgM positive but who are CMV DNA negative by PCR are eligible).",
                "criterions": [
                    {
                        "exact_snippets": "Evidence of chronic active Hepatitis B (HBV, not including patients with prior hepatitis B vaccination; or positive serum Hepatitis B antibody)",
                        "criterion": "chronic active Hepatitis B infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "chronic active Hepatitis C infection (HCV)",
                        "criterion": "chronic active Hepatitis C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "active cytomegalovirus (CMV)",
                        "criterion": "active cytomegalovirus infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "known history of HIV (or positive HIV test during screening)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "history or positive test",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "If HBc antibody is positive, the subject must be evaluated for the presence of HBV DNA by PCR. ... Subjects with positive HBc antibody and negative HBV DNA by PCR are eligible.",
                        "criterion": "HBV DNA by PCR (in HBc antibody positive subjects)",
                        "requirement": {
                            "requirement_type": "HBV DNA by PCR",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "If HCV antibody is positive, the subject must be evaluated for the presence of HCV RNA by PCR. ... Subjects with positive HCV antibody and negative HCV RNA by PCR are eligible",
                        "criterion": "HCV RNA by PCR (in HCV antibody positive subjects)",
                        "requirement": {
                            "requirement_type": "HCV RNA by PCR",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "If the subject is CMV IgG or CMV IgM positive, the subject must be evaluated for the presence of CMV DNA by PCR. ... subjects who are CMV IgG or CMV IgM positive but who are CMV DNA negative by PCR are eligible",
                        "criterion": "CMV DNA by PCR (in CMV IgG or IgM positive subjects)",
                        "requirement": {
                            "requirement_type": "CMV DNA by PCR",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Evidence of chronic active Hepatitis B (HBV, not including patients with prior hepatitis B vaccination; or positive serum Hepatitis B antibody)",
                                        "criterion": "chronic active Hepatitis B infection",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "If HBc antibody is positive, the subject must be evaluated for the presence of HBV DNA by PCR. ... Subjects with positive HBc antibody and negative HBV DNA by PCR are eligible.",
                                        "criterion": "HBV DNA by PCR (in HBc antibody positive subjects)",
                                        "requirement": {
                                            "requirement_type": "HBV DNA by PCR",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "chronic active Hepatitis C infection (HCV)",
                                        "criterion": "chronic active Hepatitis C infection",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "If HCV antibody is positive, the subject must be evaluated for the presence of HCV RNA by PCR. ... Subjects with positive HCV antibody and negative HCV RNA by PCR are eligible",
                                        "criterion": "HCV RNA by PCR (in HCV antibody positive subjects)",
                                        "requirement": {
                                            "requirement_type": "HCV RNA by PCR",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "active cytomegalovirus (CMV)",
                                        "criterion": "active cytomegalovirus infection",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "If the subject is CMV IgG or CMV IgM positive, the subject must be evaluated for the presence of CMV DNA by PCR. ... subjects who are CMV IgG or CMV IgM positive but who are CMV DNA negative by PCR are eligible",
                                        "criterion": "CMV DNA by PCR (in CMV IgG or IgM positive subjects)",
                                        "requirement": {
                                            "requirement_type": "CMV DNA by PCR",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "exact_snippets": "known history of HIV (or positive HIV test during screening)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "history or positive test",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}